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Abstract: The objective of the study was to investigate the association between maternal 
smoking, GSTM1, GSTT1 polymorphism, low birth weight (LBW, < 2,500 g) and intra-
uterine growth restriction (IUGR, < 2,500 g and gestation ≥ 37 weeks) risk. Within a 
prospective cohort study in Kaunas (Lithuania), a nested case-control study on LBW and 
IUGR occurrence among 646  women with genotyping of GSTT1 and GSTM1 
polymorphisms who delivered live singletons was conducted. Multivariate logistic 
regression analysis was used to study the association of maternal smoking and 
polymorphism in two genes metabolizing xenobiotics. Without consideration of genotype, 
light-smoking (mean 4.8 cigarettes/day) during pregnancy was associated with a small 
increase in LBW risk, adjusted OR 1.21; 95% CI 0.44 – 3.31. The corresponding odds for 
IUGR risk was 1.57; 95% CI 0.45 – 5.55. The findings suggested the greater LBW risk 
among light-smoking mothers with the GSTM1-null genotype (OR 1.91; 95% CI 0.43 – 
8.47) compared to those with GSTM1-present genotype (OR 1.11; 95% CI 0.26 – 4.47). 
When both GSTM1 and GSTT1 genotypes were considered, the synergistic effect was 
found among smoking mothers: GSTT1-present and GSTM1-null genotype OR for LBW 
was 3.31; 95% CI 0.60-18.4 and that for IUGR was 2.47; 95% CI 0.31 – 13.1. However 
there was no statistically significant interaction between maternal smoking, GSTT1- 
present and GSTM1-null genotypes for LBW (OR 1.45; 95% CI 0.22 – 10.1, p = 0.66) and 
for IUGR (OR 1.10; 95% CI 0.10 – 12.6, p = 0.93). The results of this study suggested that 
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smoking, even at a low-level, ought to be considered a potential risk factor for adverse 
birth outcomes and that genetic polymorphism may contribute to individual variation in 
tobacco smoke response. 
Keywords: Tobacco smoking; GSTM1; GSTT1 polymorphism; low birth weight risk; 
fetal growth restriction. 
 
1. Introduction  
 
Tobacco smoking is known to be associated with adverse pregnancy outcomes. The root causes of 
many adverse pregnancy outcomes are not well understood, but there is growing evidence that the 
environment can play an important role. Environmental factors that may have such effects include 
tobacco smoking, socioeconomic disparities, ambient air pollution, and various other agents 
encountered both indoors and outdoors [1]. Recent epidemiologic studies have showed, that many 
adverse pregnancy outcomes might arise from the complex interactions between genes and 
environment as a function of the age- or stage of development of the individual [2,3].  
Active maternal smoking has been associated with a number of adverse reproductive outcomes [4]. 
Among them are the increased risk of low birth weight (LBW) [5-7], intra-uterine growth restriction 
(IUGR) [8,9], and, to lesser extent, preterm birth [10]. Numerous studies have found that infants born 
to smokers weigh substantially less than infants born to nonsmokers [11,12]. Even environmental 
tobacco smoke (ETS) has been shown to have a negative impact on birth weight. Among women who 
were exposed to ETS at home and work, infants were lower in weight at delivery in comparison with 
women who were never exposed to smoke, and even lower in weight when compared with women 
who smoked during pregnancy [6,7]. Consequently, ETS is recognized as a risk factor for reduction in 
birth weight and preterm birth of infants [10].  
Tobacco smoke is a known to be toxic to humans. It contains over 3,000 chemicals of which over 
200 are regarded as poisons and 50 as possible carcinogens [13]. It is generally accepted that there is 
no safe level of exposure to cigarette smoke [14]. Maternal smoking during pregnancy can result in 
both pregnancy complications and reduced size of the fetus and neonate. Among women who smoke, 
genetic susceptibility to tobacco smoke is also a likely causative factor in adverse pregnancy outcomes 
[15]. Smoking has an even stronger impact on birth weight than alcohol, and today maternal cigarette 
smoking has been identified as the single largest modifiable risk factor for IUGR in developed 
countries [16]. However, not all women who smoke cigarettes during pregnancy have LBW infants. 
The reason for this variability is largely unknown, but may be related to maternal genetic   
susceptibility [17]. 
Tobacco smoke is a complex mixture that contains, among other substances, polycyclic aromatic 
hydrocarbons (PAHs) and N-nitrosamines. Recent studies have shown that there are associations 
between exposure to PAHs and reduced fetal growth and preterm birth [1]. One study in the Czech 
Republic found that increasing PAH levels during the first month of pregnancy increased the risk of 
fetal growth restriction [9]. Both PAHs and N-nitrosamines are genotoxic and carcinogenic, and their 
metabolic activation leads to the formation of DNA adducts [15].  Int. J. Environ. Res. Public Health. 2009, 6          
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Several different classes of enzymes take part in the process of xenobiotic metabolism and carry out 
conjugation reactions such as the well-known glutathione S-transferases (GSTs) [18,19]. The GSTs are 
a polymorph super-gene family of detoxification enzymes that are involved in the metabolism of 
numerous toxins and provide critical defense against xenobiotics. GSTT1 encoded enzymes are 
involved in the metabolism and detoxification of PAHs [20-22]. The GSTT1 enzyme is also important 
in protecting against genotoxic damage, such as sister chromatid exchanges and the formation of 
hemoglobin adducts due to the ethylene oxide present in tobacco smoke [17]. GSTM1 enzyme encodes 
a major detoxification phase enzyme that helps detoxify various xenobiotics. Deficiency in GSTM1 
activity is caused by homozygous deletion of GSTM1 and leads to various biological consequences 
[23]. Both GSTM1 - and GSTT1 enzymes exhibit genetic polymorphism (functional- and non-
functional phenotypes), that have been shown to be related to birth weight of infants [24]. Several 
allelic variants of polymorphic GSTs show impaired enzyme activity and increase the risk of fetal 
development, as well as modify the effects of maternal smoking by increasing or decreasing its risk 
[25]. One of the maternal genetic polymorphisms of GSTM1 - and GSTT1 expression is through 
modification of oxidative stress caused by maternal exposure to tobacco smoke [26]. Therefore, the 
expression of different genotypes may lead to varying susceptibility to the adverse pregnancy effects 
of cigarette smoke. 
In this study, we used a nested case-control design to examine the relationship between maternal 
smoking, the xenobiotic metabolizing gene GSTM1, GSTT1 polymorphism, and LBW, and fetal 
growth restriction risk. We hypothesized those women with the GSTM1 - and GSTT1 null genotype 
who are exposed to cigarette smoke during pregnancy are at elevated risk for adverse   
pregnancy outcomes. 
 
2. Methodology 
 
We conducted a prospective cohort study of pregnant women as a part of the European Commission 
FP6 HiWATE project [27]. This study, called the HiWATE cohort study, was carried out in the city of 
Kaunas. For genotype analysis, we used a nested case-control design to study the interactions of 
maternal smoking with GSTM1, GSTT1, and pregnancy outcomes in 646 women. The information on 
maternal smoking was obtained by means of a questionnaire.  
On their first visit to a general practitioner, all pregnant women living in Kaunas between 2007 and 
2008 were invited to join the cohort. We recruited these women for the prospective cohort study, 
enrolling them at first trimester of gestation at the four prenatal care clinics affiliated to the hospitals of 
the Kaunas University of Medicine. No compulsion of any kind was imposed on prospective 
participants for recruitment to the study. Participation was on a voluntary basis and the women were 
enrolled in the study only if they consented to participate in the cohort. We state that the study ethics 
comply with the Declaration of Helsinki. The research protocol was approved by the Lithuanian 
Bioethics Committee and oral informed consent was obtained from all subjects. 
Pregnant women of the cohort were asked to answer two questionnaires provided to them at the 
clinic. The first questionnaire was designed to determine gestational age, maternal-, social, and 
demographic characteristics, diseases, and health behavior. All participants completed this 
questionnaire. In all, 3,005 pregnant women were registered of whom 63.9% were eligible and willing Int. J. Environ. Res. Public Health. 2009, 6          
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to be enrolled into the cohort. Women whose medical records indicated that they had pregnancy-
induced hypertension, a history of diabetes mellitus or living outside the Kaunas municipality, were 
excluded from the study. A special questionnaire was evolved to interview the 1,919 women who 
agreed to participate; 76.4% of them were interviewed before delivery at hospital and blood samples 
for genetic analysis was collected. The interviews were conducted by a nurses experienced with this 
type of work. We also conducted telephone interviews to collect information from those women who 
agreed to participate in the study but were not interviewed before delivery. Telephone interviews of 
about 24% of the total enrolled women were completed within a first month after delivery. 
Outcomes of interest related to LBW and fetal growth restriction. Pregnancy outcomes were 
ascertained primary from computerized hospital admission files as well as by abstraction of medical 
records. Birth weight was abstracted from the birth certificate for all newborns. The age of gestation 
was calculated using the data of birth as reported on the birth certificate and the 1
st day of the last 
menstrual period as was ascertained at first interview, and by ultrasound examination. We defined 
newborn weight less than 2,500 g as low birth weight and intra-uterine growth restriction as infants 
with birth weight less than 2,500 g for those newborns whose gestation period was 37 weeks or longer.  
In this study “cases” were defined as women who delivered singleton, live, LBW infants 
(International Classification of Diseases ten revision (ICD-10), codes P07.0 – 07.1), or IUGR infants 
(ICD-10, codes P05.0 – 1; P05.9). Controls were defined as women who delivered singleton, live, term 
infants with birth weight 2,500 g or more. 
The genotype analysis group included all women who delivered LBW or IUGR infants and who 
blood samples for genetic analysis was collected. Random ten controls were identified for every case. 
Multiple births or newborns with major births defects were excluded. 
 
2.1. Exposure Assessment 
 
The interview contained a number of variables including demographics (age, education, family 
status); reproductive history; job characteristics; self-reported psychosocial stress; health behavior; and 
diseases. We obtained information about tobacco use in the face-to-face and telephone interviews. We 
asked the women to report their daily cigarette consumption before pregnancy as well as during 
pregnancy. We defined “smokers” as those who smoked any number of cigarettes during pregnancy. 
We compared never smokers with women who smoked during pregnancy.  
The self-reported stress of the respondents was assessed by the following thesis: my daily activities 
are very trying and stressful. Four respondent options were used to define stress: this describes my 
state (1) very well, (2) fairly well, (3) not very well, (4) not at all. Values 1 and 2 were considered to 
represent stress; 3 and 4 represented no stress.  
The GSTM1- and GSTT1-null genotypes were identified by the multiplex polymerase chain 
reaction (PCR) in peripheral blood DNA samples. This method allows the detection of the presence of 
the genotype (at least 1 allele present: AA or Aa) or its absence (complete deletion of both alleles: aa).  
Maternal blood samples were collected in vials containing EDTA and stored at a temperature of 
−20 °C. DNA was purified from the peripheral blood using DNA purification kits (MBI “Fermentas”, 
Vilnius, Lithuania). DNA concentrations were quantified with a spectrophotometer (Eppendorrf 
BioPhotometer, 61310488, Hamburg, Germany). A PCR-based study of GSTM1 and GSTT1 Int. J. Environ. Res. Public Health. 2009, 6          
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polymorphism was carried out according to the method described previously [28]. The primers used 
for PCR were as follows: 
GSTM1 forward 5′-GAA CTC CCT GAA AAG CTA AAG C-3′and reverse 5′-GTT GGG CTC 
AAA TAT ACG GTG G-3′; 
GSTT1 forward 5′-TTC CTT ACT GGT CCT CAC ATC TC-3′ and reverse 5′-TCA CCG GAT 
CAT GGC CAG CA-3′. 
As internal control, a 268-bp fragment of the human β-globin gene was coamplified with a second 
set of primers (5′-CAA CTT CAT CCA CGT TCA CC-3′) and (5′-GAA GAG CCA AGG ACA GGT 
AC- 3′) (Biomers.net – the Biopolymer factory, Germany). PCR was carried out
 in a final volume of 
25 μl. The procedure followed for PCR was: primary denaturation at 94 °C for 5 min, denaturation at 
94 °C for 1min, annealing at 60 °C for 1 min, extension at 72 °C for 1 min, 30 cycles were conducted. 
Final extension was at 72 °C for 10 min. The PCR products were electrophoresed in 2% agarose
 gels 
and stained in ethidium bromide. The DNA bands were visualised by UV transillumination (EASY 
Win32, Herolab, Germany). GSTM1 and GSTT1 polymorphisms were coded as present (GSTM1-1 
and GSTT1-1) or absent (GSTM1-0 and GSTT1-0). 
 
2.2. Statistical Methods 
 
We evaluated tobacco smoke exposure in relation to birth outcomes by calculating crude- and 
adjusted odds ratios with their 95% confidence intervals (95% CI) for the nested case-control sample. 
We used logistic regression models to estimate the individual and combined associations of maternal 
cigarette smoking and GSTM1 and GSTT1 genotypes in relation to newborn LBW and IUGR with 
adjustment for major covariates. 
Comparisons of the associations between smoking and LBW risk factors were made by using 
Fisher's exact probability test [29]. In logistic regression models for LBW, we assessed a variety of 
potential confounders, identified from the literature and by univariate analysis. These included: 
maternal age, pre-pregnancy body mass index (BMI = weight/height²) and blood pressure, parity and 
prior pregnancy history, diseases, education, marital status, employment status and hours worked, 
stress level, and alcoholic beverage consumption. 
Using personal data of the nested case-control sample, we first examined the association between 
smoking and birth outcomes without consideration of genotypes. Further, we examined the combined 
association of maternal cigarette smoking and maternal genotypes with birth outcomes controlling for 
effect of major covariates that changed the adjusted odds ratio for smoking by 10% or more. The 
subgroups were defined for LBW and IUGR and by maternal smoking status during pregnancy (no vs 
yes) and genotype for GSTT1 (present vs absent) and GSTM1 (present vs absent). We used chi-square 
tests to examine the association between genetic polymorphisms and individual susceptibility to 
tobacco smoking. The gene-cigarette smoke interaction was also tested by adding a product term to the 
regression models. All the analyses were adjusted for following potential effect modifiers viz. maternal 
age, BMI, education, and marital status.  
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3. Results and Discussion 
 
3.1. Results 
 
Among the pregnant women with smoking and pregnancy outcome data, 71.1% never smoked, 
21.5% smoked before but not during pregnancy. Among the women who smoked during pregnancy, 
light smokers (mean 4.8 cigarettes/day) predominated (92.3% of smokers) and only 7.7% of smokers 
smoked 10 or more cigarettes per day. In this cohort of women receiving prenatal care at a health 
maintenance organization, 5.0% of infants had LBW, 5.2% were born preterm, and 2.0% were small 
for gestational age (intrauterine growth restriction, IUGR). 
Table 1 presents maternal characteristics by tobacco smoke-exposure status. This is the overall low-
risk population, with the majority of women at their optimal reproductive ages, high education, most 
having the ideal BMI, blood pressure, and most non-smokers. Smoking during pregnancy was 
associated with maternal age, education, marital status, and smoking history before pregnancy: the P 
value of exact test was p < 0.05. Infants of active smokers revealed non-significant reduction in mean 
birth weight: among non-smokers, the birth weight was 3445  25 g, and light smokers – 3365  59, 
 p = 0.2. 
 
Table 1. Percent distribution of subjects by smoking for various characteristic and   
pregnancy outcomes. 
Maternal characteristics   Total  Smoking during pregnancy (%)  Exact test 
Variables N  None  Yes  p 
Age: 
 ≤ 20 y 
 21 –  30 y 
 >30 y 
 
28 
402 
216 
 
71.4 
86.8 
92.1 
 
28.6 
13.2 
7.9 
 
 
 
0.004 
Education: 
 university 
 college and ≤ 12 y 
 
309 
337 
 
96.8 
79.8 
 
3.2 
20.2 
 
 
< 0.001 
Marital status:  
 married 
 not married 
 
493 
153 
 
92.3 
73.9 
 
7.7 
26.1 
 
 
< 0.001 
Parity:  
 1
st 
 2
rd and more 
 
320 
326 
 
89.1 
86.8 
 
10.9 
13.2 
 
 
0.38 
Pregnancy history: 
 no prior 
 losses 
 
517 
129 
 
87.2 
90.7 
 
12.8 
9.3 
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Table 1. Cont. 
Gestational age: 
 ≥ 37 weeks 
 < 37 weeks 
 
600 
46 
 
87.5 
93.5 
 
12.5 
6.5 
 
 
0.23 
Blood pressure: 
 ≤ 140 –  90 mm/Hg 
 > 140/90 mm/Hg 
 
558 
88 
 
87.8 
88.6 
 
12.2 
11.4 
 
 
0.83 
Stress: 
 no  
 yes 
 
523 
123 
 
88.5 
85.4 
 
11.5 
14.6 
 
 
0.33 
Mother diseases: 
 no 
 yes 
 
474 
172 
 
88.8 
85.5 
 
11.2 
14.5 
 
0.25 
Body mass index (BMI): 
 normal - overweight (25.1 – 30) 
 obesity (> 30) 
 
558 
88 
 
87.8 
88.6 
 
12.2 
11.4 
 
0.83 
Smoking before pregnancy:  
 none 
 1 –  9 cigs./d. 
 > 9 cigs./d. 
 
461 
169 
16 
 
100.0 
60.4 
31.3 
 
0.0 
39.6 
68.8 
 
 
 
< 0.001 
Smoking duration before pregnancy: 
 non smoker 
 1 –  5 y 
 6 – 10 y 
 > 10 y 
 
461 
122 
47 
16  
 
100.0 
66.4 
44.7 
31.3 
 
0.0 
33.6 
55.3 
68.7 
 
 
 
 
< 0.001 
Mean birth weight (g), ± SD  3,436 ± 24  3,445 ± 25  3,365 ± 59  0.21 
 
Table 2 presents variables that were associated with maternal smoking and other known LBW risk 
factors and provides inferential statistics, that is, odds ratios and 95 percent confidence intervals for 
the discrete variables. In univariate analyses, increasing number of cigarettes smoked was associated 
with an increased risk in LBW infants. Smokers of 9 cigarettes and more per day had crude odds ratios 
1.97 (95% CI 0.78-5.02) times those of unexposed women; however, a small number of LBW cases 
were reported among smokers and that had an effect on the statistical significance of the results. Age, 
marital status and blood pressure had statistically significant effect on LBW risk. These risk factors 
were incorporated into multivariate logistic regression models. Variables that were associated with 
IUGR risk were same as LBW.  
 
Table 2. Distribution of maternal characteristics among low birth weight (LBW) cases and 
controls, odds ratios (OR) and their 95% confidence intervals (CI). 
Maternal characteristics 
Cases LBW  Controls  Inferential statistics 
N % N  % OR  95%  CI 
Age: 
 21 – 30 y 
 ≤ 20 y 
 > 30 y 
 
26 
5 
26 
 
45.6 
8.8 
45.6 
 
376 
23 
190 
 
63.8 
3.9 
32.3 
 
1 
3.14 
1.98 
 
 
1.11 – 8.94 
1.12 – 3.50 Int. J. Environ. Res. Public Health. 2009, 6          
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Table 2. Cont. 
Education: 
 university  
 college & < 12 y 
 
28 
29 
 
49.1 
50.9 
 
281 
308 
 
47.7 
52.3 
 
1 
0.95 
 
 
0.55 – 1.63 
Marital status: 
 married 
 not married 
 
37 
20 
 
64.9 
36.1 
 
456 
133 
 
77.4 
22.6 
 
1 
1.85 
 
 
1.04 – 3.30 
Parity: 
 1
st  
 2
nd and more 
 
26 
31 
 
45.6 
54.4 
 
294 
295 
 
49.9 
50.1 
 
1 
1.19 
 
 
0.69 – 2.05 
Previous pregnancy history: 
 no prior 
 losses 
 
42 
15 
 
73.7 
26.3 
 
475 
114 
 
80.6 
19.4 
 
1 
1.49 
 
 
0.80 – 2.78 
Blood pressure: 
 ≤ 120/80 – 140 – 90 mm/Hg 
 > 140/90 mm/Hg 
 
52 
5 
 
91.2 
8.8 
 
506 
83 
 
85.9 
14.1 
 
1 
0.59 
 
 
0.23 – 1.51 
Stress: 
 no 
 yes 
 
45 
12 
 
78.9 
21.1 
 
478 
111 
 
81.2 
18.8 
 
1 
1.15 
 
 
0.59 – 2.24 
Mother diseases: 
 no 
 yes 
 
41 
16 
 
71.9 
28.1 
 
433 
156 
 
73.5 
16.5 
 
1 
1.08 
 
 
0.59 – 1.99 
Body mass index (BMI): 
 BMI > 30 
 BMI ≤ 30 
 
7 
50 
 
12.3 
87.7 
 
135 
454 
 
22.9 
77.1 
 
1 
2.12 
 
 
0.94 – 4.79 
Smoking during pregnancy:  
 non smoker 
 ≤ 9 cig. 
 > 9 cig. 
 
39 
17 
1 
 
68.4 
29.8 
1.8 
 
422 
152 
15 
 
71.6 
25.8 
2.5 
 
1 
0.87 
1.97 
 
 
0.45 – 1.68 
0.78 – 5.02 
 
In terms of GSTT1 and GSTM1 genotype frequency, women in the group exposed to tobacco 
smoke and the groups not exposed were similar. Table 3 presents the combined association of maternal 
cigarette smoking and maternal genotypes with LBW controlling for effect of major covariates. 
The percentage of GSTT1 absent genotype was 16.9% and that of GSTM1 was 46.6%. As shown 
in Table 3, without consideration of genotype, maternal smoking during pregnancy was associated 
with an adjusted OR of 1.21 (95% CI 0.44 – 3.31) for LBW compared with the non – smokers. When 
GSTT1 genotype was considered, the association between maternal smoking and LBW increased and 
the adjusted OR was 2.06 (95% CI 0.67 – 6.37) among mothers with genotype present, but we could 
not assess the association among mothers with absent genotype because of 0 LBW cases in the 
smokers group.  
When GSTM1 genotypes were considered, the association between maternal smoking and LBW 
differed: the adjusted OR was 1.11 (95% CI 0.26 – 4.76) among mothers with present but adjusted OR 
was 1.91 (95% CI 0.43–8.47) among mothers with absent genotypes. However, a test of interaction 
between smoking and the GSTM1 – null genotype showed that there was no statistically significant 
evidence for an effect modification adjusted OR 1.54; 95% CI 0.25 – 9.91, p = 0.59. Presence of both Int. J. Environ. Res. Public Health. 2009, 6          
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GSTT1 and GSTM1 genotypes tended to increase the smoking effect by 1.49, while the GSTT1 – 
present genotype and GSTM1 – null genotype were associated with 3.31 times higher risk among 
smokers (OR 3.31 95% CI 0.60–18.4). A test of interaction between maternal smoking and two studied 
genotypes did not confer a significant adverse effect on LBW risk, adjusted OR 1.45; 95% CI 0.22 – 
10.1, p = 0.66. 
 
Table 3. Crude and adjusted associations as odds ratios (OR) maternal smoking during 
pregnancy with low birth weight by maternal genotypes. 
Genotype 
Smoking 
status 
N LBW, 
% 
Crude 
OR 95% CI 
Adjusted* 
OR 95% CI 
Total sample 
 
Never 342  8.8     
Quitter  86  10.5  1.22 0.55 – 2.67  1.18 0.53 – 2.62 
Smoking  52  11.5  1.36 0.54 – 3.44  1.21 0.44 – 3.31 
GSTT1 
Present 
Never 289  9.0     
Smoking  38  15.8  1.90 0.73 – 4.96  2.06 0.67 – 6.37 
GSTT1 
Absent 
Never 53  7.5     
Smoking 14  0     
GSTM1  
Present  
Never 168  8.9     
Smoking  31  9.7  1.09 0.30 – 4.0  1.11 0.26 – 4.76 
GSTM1 
Absent 
Never 174  8.6     
Smoking  21  14.3  1.77 0.47 – 6.69  1.91 0.43 – 8.47 
٭٭Interaction: smoking x GSTM1 
absent 
OR 1.62 (0.25 – 10.4), p = 0.60; OR* 1.54 (0.25 – 9.91), p = 
0.59 
GSTT1 & GSTM1 
Present 
Never 145  9.7     
Smoking  22  13.6  1.48 0.39 – 5.62  1.49 0.33 – 6.79 
GSTT1 present & 
GSTM1 absent 
Never 144  8.3     
Smoking  16  18.8  2.54 0.63 – 10.2  3.31 0.60 – 18.4 
٭٭Interaction: smoking x GSTT1 
present & GSTM1 absent 
OR 1.72 (0.25 – 11.8), p = 0.58; OR* 1.45 (0.22 – 10.1), p = 
0.66 
*Logistic regression model: women BMI ≤ 30, age ≥ 20 years, adjustment for maternal education and 
marital status. 
**Test of interaction: a P value is presented for testing the null hypothesis, odds ratio = 1.0 in logistic 
regression models for the product term, smoking x genotypes. 
 
Table 4 presents the combined association of maternal smoking and GSTT1 – and GSTM1 
genotypes with IUGR. Without considering genotypes, maternal smoking during pregnancy was 
associated with an adjusted OR of 1.57 (95% CI 0.45–5.55) for IURG compared with the non – 
smokers. 
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Table 4. Crude and adjusted associations as odds ratios (OR) maternal smoking during 
pregnancy with intrauterine fetal growth restriction by maternal genotypes. 
Genotype 
Smoking 
status 
N LBW,   
% 
Crude 
OR 95% CI 
Adjusted* 
OR 95% CI 
Total sample 
 
Never 325  4.0     
Quitter  80  3.8  0.94 0.26 – 2.36  0.85 0.23 – 3.10 
Smoking  50  8.0  2.09 0.65 – 6.68  1.57 0.45 – 5.55 
GSTT1 
Present 
Never 274  4.0     
Smoking  36  11.1  2.99 0.90 – 9.94  2.63 0.65 – 10.6 
GSTT1 
Absent 
Never 51 3.9     
Smoking 14  0     
GSTM1  
Present 
Never 158  3.2     
Smoking  30  6.7  2.19 0.40 – 11.8  2.00 0.30 – 13.2 
GSTM1 
Absent 
Never 167  4.8     
Smoking  20  10.0  2.21 0.44 – 11.2  1.70 0.28 – 10.4 
٭٭Interaction: smoking x GSTM1 
absent 
OR 1.01 (0.10 – 10.5), p = 0.99; OR* 0.98 (0.09 – 10.3), p = 0.99 
GSTT1 & GSTM1 
Present 
Never 136  3.7     
Smoking  21  9.5  2.76 0.50 – 15.2  2.66 0.38 – 18.5 
GSTT1 present & 
GSTM1 absent 
Never 138  4.3     
Smoking  15  13.3  3.39 0.62 – 18.5  2.47 0.31 – 13.1 
٭٭Interaction: smoking x GSTT1 
present & GSTM1 absent 
OR 1.23 (0.11 – 13.7), p = 0.87; OR* 1.10 (0.10 – 12.6), p = 0.93 
*Logistic regression model: women BMI ≤30, age ≥ 20 years, adjustment for maternal education and marital 
status. **Test of interaction: a P value is presented for testing the null hypothesis, odds ratio =1.0 in logistic 
regression models for the product term, smoking x genotypes. 
 
When we considered genotype GSTT1, the association between tobacco smoke exposure and IURG 
tended to be higher, and adjusted OR was found to be 2.63 (95% CI 0.65 – 10.6) among the mothers 
group with GSTT1 genotype present. The estimated smoking effect tendered to be higher among 
mothers with the GSTM1 – null allele, compared with non-smoking mothers OR was 1.70 (95% CI 
0.28 – 10.4). We found some evidence of synergistic effect the GSTT1 and GSTM1 genotypes and 
active maternal smoking: OR were 2.66 (95% CI 0.38 – 18.5) for both alleles present and OR 2.47 
(95% CI 0.31 – 13.1) for GSTM1 absent; nevertheless, there was no statistically significant 
interaction, adjusted OR 1.10; 95% CI 0.10 – 12.61, p = 0.93. 
 
3.2. Discussion 
 
In this molecular epidemiological study on maternal cigarette smoking and genetic determinants of 
xenobiotic metabolism, we found some evidence that effects of maternal smoking on LBW risk and 
infant growth were increased by maternal GSTM1 null genotype. This study used a case-control Int. J. Environ. Res. Public Health. 2009, 6          
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design to analyze the genetic effects and the gene-environment interaction controlling for major 
confounding variables. Consistent with previous studies, we found that maternal cigarette smoking was 
associated with fetal growth restriction and increased risk of LBW risk [5,17]. Our findings are 
consistent with a number of other studies that LBW risk may vary in relation to maternal age, BMI, 
parity, and other variables of the population in the study [29-31]. Some other investigators who have 
examined the issue, revealed dose-response gradients in relation to the amount smoked [4,33].  
 Present our findings show the greater LBW risk among light-smoking mothers with GSTM1 null 
genotype compared to those with GSTM1 present genotype, however the findings do not show a 
statistically significant results. These results are consistent with previous studies which analysed 
genetic susceptibility to cigarette smoke in the context of LBW or IUGR risk. 
 Wang et al. reported that pregnant women with certain genotypes are susceptible to the adverse 
pregnancy effects of tobacco smoking, such as an increased risk of LBW [17]. Without consideration 
of genotype, maternal smoking during pregnancy was associated with reduction in birth weight and 
elevated risk of LBW. When GSTT1 genotype was considered, the reduction in birth weight increased 
and 1.7 (0.9 – 3.2) - fold elevated risk of LBW for those with the genotype present, and 3.5 (1.5 – 8.3) 
- fold elevated risk of LBW for GSTT1 genotype absent was found among smoking mothers. The 
corresponding features for IUGR were 3.3 (1.7 – 6.3) and 2.5 (0.9 – 6.4), suggesting an interaction 
between metabolic genes and maternal smoking.  
It has been reported that an individual difference in metabolic activation and detoxification 
xenobiotics partly depends on the genetic polymorphisms associated with GSTT1 and GSTM1 
enzymes [33]. The interactive effect of exposure to tobacco smoke and the presence of the GSTT1 
polymorphism on infant birth weight was found to be significant by multivariate analysis, whereas the 
interactive effect of the presence the GSTM1 polymorphism did not reach statistical significance   
(p = 0.21) [25]. 
Sasaki et al. also reported combined effects between maternal genetic polymorphisms and smoking 
during pregnancy [35]. The effects on reduction birth weight were not observed among women with 
GSTM1 null genotype who had never smoked. The authors conclude that maternal smoking in 
combination with maternal genetic susceptibility may adversely affect infant birth weight. However, 
results presented here do not show a statistically significant association between infant birth size and 
maternal smoking as linked to the GSTT1 genotype, while birth weight and length were significantly 
lower in subjects with GSTM1 null genotype. 
Sram  et al. found that the risk of LBW and prematurity was significantly increased by the 
genotypes of GSTM1 null and a genotype combination with the CYP1A1*2A genotype [36]. A survey 
among pregnant women have shoved that a combination of the GSTM1 null and the GSTT1 null 
genotypes exacerbate the effect of maternal exposure to tobacco smoke on birth weight more than the 
presence of either genotype one [24]. 
Different results were presented by some authors [25]. In the case-control study, controlling for 
several confounding factors, the authors revealed that the maternal GSTT1 null genotype had a 1.6 – 
fold reduced risk for small-for-gestational-age births. However, after adjustment for maternal smoking 
(categories less than 10 cigarettes/day and more than 10 cigarettes/day) the results were not 
statistically significant. Int. J. Environ. Res. Public Health. 2009, 6          
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There is evidence that effect of cigarette smoke exposure depends on population characteristics: 
among Japanese GSTM1 null genotype decreases fetal growth but this effect is not observed in 
Caucasians. Moreover, the adverse effect on birth weight did not always accompany fetal growth 
restriction [37]. 
Previous studies have suggested several plausible gene-smoking interaction explanations. First, 
tobacco smoke could disturb fetal and placental cellular regulation via elevated PAH-DNA adducts 
due to the increased activity of enzymes that metabolize cigarette toxins (e.g. CYP1A1) and lower or 
absent activity of enzymes that detoxify these compounds (e.g. GSTT1 and GSTM1 null genotypes) 
[15]. Second, gene-smoking interactions may exert their synergistic effects through oxidative stress 
that occurs upon tobacco smoke exposure. In response to this stress various inflammatory cytokines 
are produced in lung tissue increasing inflammatory responses and immune responses [38]. Moreover, 
as reported by some authors, maternal exposure to tobacco smoke affects the fetal urine cotinine 
concentration and also induces production of oxidative stress [26]. Further, other environmental 
factors and genetic polymorphism of GSTM1 and GSTT1 may modify the response to oxidative stress 
and lead to adverse pregnancy outcomes [32]. 
In this study, we demonstrated that there is increase in LBW and IUGR risk among smoking 
women even after adjusting for maternal age, education, BMI, and marital status; however, these 
findings suggest that there was no significant association between the GSTT1 and GSTTM1 
polymorphism with low-level maternal smoking during pregnancy. The reason may be that the size of 
our nested case-control study and the proportion of women who smoked during pregnancy were too 
small to detect any significant difference. 
 Consistent to previous studies, we found that the effect of tobacco smoke increased LBW risk in 
the women’s group with combination of GSTT1 present and GSTM1 absent alleles was more than 3 
times greater compared with the non-smokers group (OR 3.31; 95% CI 0.6 – 18.4). Similar evidence 
of the synergic effect of GSTT1 and GSTM1 polymorphism we revealed on fetal growth restriction, 
adjusted OR 2.47; 95% CI 0.31 – 13.1. The adverse effects of GSTM1 null genotype on IUGR in the 
presence of cigarette smoke exposure were observed even among light smokers. These data strengthen 
the previous research findings that indicated that subjects with GSTM1 null genotype have a greater 
risk of toxic tobacco smoke effects while restricted fetal growth among light smokers provides 
evidence of unhealthy development in uterus [35]. 
When the results of this study are interpreted, a few conditions should be taken into account. This is 
a low-risk population with low-level tobacco smoke exposure, and low prevalence of GSTT1 null 
genotypes and these factors may limit extrapolation of these results to the other populations. The 
evaluation of exposure to tobacco smoke was indirect; we used self-reported information on smoking 
during- and before pregnancy, and thus the possibility of reporting bias exists. Because of the 
subjective measure of smoking exposure, there is a possibility of random exposure classification 
errors. However, in this study, we controlled for the main variables that might confound the 
association between smoking, genetic polymorphism, and birth outcomes, among them age, BMI, 
education, and family status, therefore, the residual confounding of results by smoking is expected to 
be small. 
Our findings stress the need for appropriate policy and programs aimed at cessation of tobacco use 
among pregnant women. The evidence of increased risk of adverse birth outcomes in presence of Int. J. Environ. Res. Public Health. 2009, 6          
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genetic polymorphism reinforces the motivation argument for quitting smoking. This could help in 
directing smoking cessation interventions toward pregnant women and prevent adverse birth outcomes 
since smoking prevalence rate and effectiveness of tobacco control programs mostly depend not only 
on legislative recourses, but also on the individual perceiving that smoking is harmful to health 
[39,40]. 
 
4. Conclusions  
 
In summary, we have demonstrated that tobacco smoke exposure, even at a low-level, is associated 
with fetal growth restriction. Such as association, however, is modified by an individual’s genotype. 
This study supports the importance of considering genetic susceptibility in prevention of adverse birth 
outcomes and evaluation of the effectiveness of anti-smoking preventive programs. 
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